Special report on the Sanofi-Aventis cardiometabolic symposium.
D052242:Adiponectin / Q000097:blood; D000273:Adipose Tissue / Q000503:physiopathology; D000465:Algorithms; D002097:C-Reactive Protein / Q000032:analysis; D063387:Cannabinoid Receptor Antagonists; D003920:Diabetes Mellitus / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000453:epidemiology; D005951:Glucose Tolerance Test; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000097:blood / Q000502:physiology; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D009765:Obesity / Q000453:epidemiology; D010316:Particle Size; D010880:Piperidines / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011720:Pyrazoles / Q000627:therapeutic use; D043882:Receptors, Cannabinoid / Q000187:drug effects; D000077285:Rimonabant; D018570:Risk Assessment; D012307:Risk Factors
D052242:Adiponectin; D063387:Cannabinoid Receptor Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D002097:C-Reactive Protein; D000077285:Rimonabant